🟢 Milestone Pharmaceuticals is trading 5.54% up in after-hours trading with no identified catalyst

Milestone Pharmaceuticals is trading at $0.81, up 5.54%, with no specific catalyst identified for its October 6 after-hours gain.

• No new company announcement explaining the rise was identified; the latest company release, on September 24, updated enrollment in its ReVeRA-301 Phase 3 trial.
• The broader market was supportive on October 6: the S&P 500 rose 0.62% and Nasdaq Composite gained 0.70%, but available evidence does not directly link that strength to the after-hours move.